|
US2018042868A1
|
|
Tamper resistant formulation of ephedrine and its derivatives
|
|
WO2018007507A1
|
|
Reinforced pharmaceutical dosage form
|
|
US2017273970A1
|
|
Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
|
|
WO2017182425A1
|
|
Pharmaceutical dosage form mountable to a tooth
|
|
US2017296476A1
|
|
Modified release abuse deterrent dosage forms
|
|
US2017112766A1
|
|
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
|
WO2017108203A1
|
|
Novel substituted indoline compounds as phosphodiesterase inhibitors
|
|
WO2017114596A1
|
|
Crystalline forms of (cis)-n-(4-(dimethylamino)-1,4-diphenylcyclohexyl)-n-methyl-cinnamamide
|
|
WO2017114597A1
|
|
Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide
|
|
WO2017021397A1
|
|
Phase separator
|
|
WO2016180543A1
|
|
In vitro screening assay for thermoneutral trpv1 modulators
|
|
EP3286196A1
|
|
Crystalline salts of hydrocodone bitartrate
|
|
AU2016251851A1
|
|
Tamper-resistant fixed dose combination providing fast release of two drugs from particles
|
|
WO2016096140A1
|
|
Process for the preparation of 1-[(heteroaryl)-methyl]- or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas
|
|
EP3130590A1
|
|
Aromatic aza compounds as vr1/trpv1 ligands
|
|
EP3130589A1
|
|
Heterocyclic aza compounds
|
|
US2016016937A1
|
|
Substituted pyrimidine compounds
|
|
AR101198A1
|
|
PYRIMIDINES 2,5-REPLACED AS PDE4B INHIBITORS
|
|
AR101197A1
|
|
PYRIMIDINES 2,5-REPLACED
|
|
WO2015197188A1
|
|
Pyrazolyl-based carboxamides as crac inhibitors
|
